Three years ago, diacetyl was a headline in a different kind of story. The buttery flavoring chemical, used to give microwave popcorn its rich taste, had ravaged the lungs of factory workers. “Popcorn lung,” they called it.
Bronchiolitis obliterans. A sentence for the men and women who breathed it in, day after day.
Now, the same chemical shows up in e-cigarette vapor. It travels into users’ bloodstreams at measurable levels. The difference this time is the delivery system.
It’s not a factory line. It’s a teenager’s pocket.
The American Heart Association’s scientific sessions in Dallas this week laid that connection bare. Multiple studies presented there traced a line from the flavoring compounds and solvents inside vape cartridges to damaged blood vessels. The endothelial cells that line arteries — the delicate, single-layer tissue that controls how blood flows — get inflamed.
When those cells are angry, they don’t relax. Arteries stiffen. Blood pressure climbs.
It is a slow process. It is not the sledgehammer of a traditional cigarette.
The researchers described it as a low-grade jackhammer. Constant. Grinding.
Still damage. Acrolein is another chemical in the story.
It is a breakdown product of propylene glycol, a common base liquid in e-liquids. Propylene glycol is generally recognized as safe for ingestion. The Food and Drug Administration allows it in food and cosmetics.
But heating it, turning it into an aerosol, and inhaling it deep into the lungs changes the chemistry. Acrolein forms. It is a known tissue irritant.
It is also a component of tear gas. In the blood of young adults who vape regularly, researchers tracked biomarkers showing oxidative stress.
The body was running in fight-or-flight mode. Adrenaline-like compounds were elevated. That wears on the heart muscle.
It is not subtle, as Dr. Rose Marie Robertson, the AHA’s deputy chief science and medical officer, told the sessions. The history here matters.
E-cigarettes entered the U.S. market around 2007. They were marketed as a smoking cessation tool. A way to quit.
A harm-reduction product. The pitch was simple: no tar, no combustion, no cancer. The early studies focused on lungs.
Cancer risk. Respiratory illness.
The cardiovascular system was an afterthought. It took years for researchers to look at the blood vessels, the heart muscle, the endothelial lining. The AHA data now shows those systems are not spared.
The chemicals are not inert. They are not harmless just because they are not smoke.
Diacetyl was banned from popcorn factories after the workers got sick. It was never banned from e-cigarettes. The same oversight gap applies to acrolein.
The regulatory framework for vaping products has been slow, contested, and inconsistent. The FDA only began requiring premarket review for e-cigarettes in 2016, nearly a decade after they hit the market. The deadlines have been delayed by lawsuits and policy reversals.
Meanwhile, millions of Americans have been using these devices. The studies out of Dallas this week are catching up to that real-world experiment.
The data draws a clear line. The chemicals are in the bloodstream. The damage is measurable.
The practical upshot for users is not a warning about lung cancer. It is a warning about hypertension.
About arterial stiffness. About a heart that never gets to rest. The fight-or-flight state the researchers documented is not a metaphor.
It is a measurable biological condition. It is the body’s stress response running on a loop. That wears on the heart muscle.
It is not a sledgehammer. It is a constant, low-grade jackhammer.
The damage looks different. But it is still damage.
